Timber Pharmaceuticals, Inc.
TMBR
TMBR was delisted on the 28th of November, 2023.
6 hedge funds and large institutions have $188K invested in Timber Pharmaceuticals, Inc. in 2020 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 4 closing their positions.
38% more capital invested
Capital invested by funds: $136K → $188K (+$52K)
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
20% more funds holding
Funds holding: 5 → 6 (+1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$255K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$23.8K |
| 3 |
VF
Virtu Financial
New York
|
+$17.6K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.53K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$81 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$117K |
| 2 |
Morgan Stanley
New York
|
-$7K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.77K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCM
1
Bridgeway Capital Management
Houston,
Texas
| $157K | +$255K | +3,166 | New |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $15K | +$23.8K | +295 | New |
|
|
VF
3
Virtu Financial
New York
| $11K | +$17.6K | +218 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $4K | -$1.77K | -22 | -23% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $1K | +$1.53K | +19 | New |
|
|
6
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$117K | -1,074 | Closed |
|
|
7
Morgan Stanley
New York
| – | -$7K | -60 | Closed |
|
|
8
Bank of America
Charlotte,
North Carolina
| – | -$2K | -19 | Closed |
|
|
9
Wells Fargo
San Francisco,
California
| – | +$81 | +1 | New |
|
TMBR Hedge Fund Activity: Q3 2020 in Review
6 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Timber Pharmaceuticals, Inc. (TMBR) for Q3 2020, worth a combined $188K — up 38% from $136K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TMBR positions and 4 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $255K. The largest seller was Deutsche Bank, exiting entirely with an estimated $117K sold.
- 6 institutional investors held Timber Pharmaceuticals, Inc. (TMBR) as of Q3 2020, up from 5 in Q2 2020.
- Funds reported $188K of Timber Pharmaceuticals, Inc. stock for Q3 2020, up 38% quarter-over-quarter.
- 5 funds opened new Timber Pharmaceuticals, Inc. positions in Q3 2020 and 4 closed out, a net change of +1 holder.
- The largest Timber Pharmaceuticals, Inc. buyer in Q3 2020 was Bridgeway Capital Management, an estimated $255K added.
- The largest Timber Pharmaceuticals, Inc. seller in Q3 2020 was Deutsche Bank, an estimated $117K sold.
Based on aggregated 13F filings for Q3 2020.